Tratamiento de la quilomicronemia
| Autor: | Alicia Navarro Hermoso, Pedro Valdivielso |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty Apolipoprotein B media_common.quotation_subject 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Diabetes mellitus Injection site medicine Pharmacology (medical) Platelet 030212 general & internal medicine media_common Triglyceride biology business.industry medicine.disease chemistry Weekly dose biology.protein Acute pancreatitis Cardiology and Cardiovascular Medicine business |
| Zdroj: | Clínica e Investigación en Arteriosclerosis. 33:75-79 |
| ISSN: | 0214-9168 |
| DOI: | 10.1016/j.arteri.2021.01.004 |
| Popis: | Fasting chylomicronaemia appears in type V (multifactorial chylomicronaemia syndrome, MCS), and in type I (familial chylomicronaemia syndrome, FCS). MCS needs to be treated as in any general hypertriglyceridaemia: low-calorie diet, avoid sugar and alcohol, reduce body weight, control of diabetes and, in some cases, common lipid lowering-drugs, such as fibrates or omega-3 fatty acids. For type I HLP, FCS, patients should adhere to a strict very low fat diet, usually less than 15-20 g per day. In spite of this, many patients with FCS suffer from recurrent abdominal pain and/or acute pancreatitis. Volanesorsen, an antisense oligonucleotide against apolipoprotein C-III, is the only drug approved to control the disease. As shown in the APPROACH study, the administration of volanesorsen at a weekly dose of 285 mg induced at three month a reduction of triglycerides of 77% (primary end-point) and a reduction of 1712 mg/dL from the baseline. Among patient receiving volanesorsen, 77% reached a fasting triglyceride value below 750 mg/dL. The most frequent side effects were a skin reaction at injection site and low platelet levels, which should be monitored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|